The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: T
- PDF / 602,421 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 19 Downloads / 131 Views
ORIGINAL RESEARCH
The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study Naveen Seecheran
. Arvinash Ramdeen . Niranjan Debideen . Kabeer Ali . Kathryn Grimaldos .
Gabriella Grimaldos . Abhinav Karan . Rajeev Seecheran . Valmiki Seecheran . Sangeeta Persad . Harun Abdullah . Lakshmipathi Peram . Stanley Giddings . Shastri Motilal . Antonio Tello-Montoliu . David Schneider Received: October 19, 2020 / Accepted: November 25, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: This prospective pharmacodynamic (PD) study aimed to assess the effect of the sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin on platelet reactivity. Methods: Patients with stable coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) (n = 20) who were actively treated with dual antiplatelet therapy (DAPT) of aspirin 81 mg daily and clopidogrel 75 mg daily were recruited. Platelet function was measured with the VerifyNowTM P2Y12 assay (Instrumentation Laboratory, Massachusetts, USA) and assessed before the initiation of and after 10 days of treatment with empagliflozin 25 mg once daily
N. Seecheran (&) S. Giddings S. Motilal The University of the West Indies, St. Augustine, Trinidad and Tobago e-mail: [email protected]; [email protected] A. Ramdeen N. Debideen K. Ali K. Grimaldos G. Grimaldos A. Karan R. Seecheran V. Seecheran S. Persad H. Abdullah L. Peram North Central Regional Health Authority, Mount Hope, Trinidad and Tobago A. Tello-Montoliu Universidad de Murcia, Murcia, Spain D. Schneider Cardiovascular Research Institute of Vermont, Colchester, VT, USA
maintenance dose regimen. Results were compared with a paired t test. Results: The mean P2Y12 reaction units (PRU) on empagliflozin was significantly less than without empagliflozin at baseline (187.35, 95% confidence interval (CI) 155.38–219.32 vs. 217.25, CI 180.60–253.90; p \ 0.030). The mean difference in PRU was 29.90 (95% CI 3.17–56.63). No patients experienced any serious adverse events (SAEs). Conclusions: Significantly attenuated platelet reactivity was observed on empagliflozin as compared to without empagliflozin. This dedicated pharmacodynamic study could be clinically pertinent for Trinidadian patients with stable CAD and T2DM on DAPT. Further studies are required to confirm these exploratory findings. (Funded by the University of the West Indies, St. Augustine; EFFECT). Clinical Trial Registration: ClinicalTrials.gov number NCT04342819. Keywords: Empagliflozin; Platelet reactivity; Platelet function; Sodium–glucose cotransporter 2 inhibitor (SGLT2i); VerifyNowTM
Cardiol Ther
Key Summary Points Why carry out this study? Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have emerged as pivotal therapies for patients with type 2 diabetes mellitus (T2DM). Several largescale randomized clinical trials, such as the EMPA-REG OUTCOME and DAPA-HF, have demonstrated a considerable reduction in major adverse cardiovascular events
Data Loading...
